Orbit Discovery, a leader in peptide discovery services, and Evergreen Theragnostics, a pioneer in radiopharmaceuticals and precision medicine, today announced the extension of their research collaboration to develop innovative targeting peptides for radiopharmaceutical applications. This expansion builds on a previous agreement established in April 2023, where mutual technology strengths facilitated the discovery of high-affinity peptide ligands tailored for precision therapeutic use.
The expanded partnership will employ Orbit Discovery’s proprietary screening technology to pinpoint and refine peptide candidates, in conjunction with Evergreen Theragnostics’ proficiency in radiopharmaceutical development and clinical adaptation. This enduring partnership highlights a shared commitment to advancing next-generation targeted therapies, focusing on speed, precision, and effectiveness.
“Our collaboration with Evergreen Theragnostics continues to illuminate the profound innovations possible when complementary expertise joins forces,” said Dr. Neil Butt, CEO of Orbit Discovery. “We are eager to build on our successes, utilizing our proprietary platform to discover peptides with the potential for therapeutic advancement.”
Dr. Butt further remarked, “Evergreen Theragnostics offers extensive radiopharmaceutical expertise, providing a robust base for transforming peptides into advanced therapeutic solutions, particularly in oncology. This partnership demonstrates the shared dedication of both companies to offering patient-focused solutions in the rapidly expanding field of radiopharmaceuticals.”
“We are excited to further our collaboration with Orbit Discovery,” stated Dr. Thomas Reiner, CSO of Evergreen Theragnostics. “The peptide discovery platform has been pivotal in our endeavor to create precision-targeted radiopharmaceuticals. Together, we aim to accelerate the journey from discovery to clinical practice, developing new therapies that have the potential to significantly improve outcomes for cancer patients.”